Collins Helen Louise

CHIEF MEDICAL OFFICEREnliven Therapeutics, Inc. (ELVN) · full profile →Form 4 · filed May 20, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$199K
Net Open-Market Flow
-$199K
Transactions
5
4 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 18, 2026Option exercise(M)5K$2.48$12K30K
May 18, 2026Sell(S)3K$39.53$137K27K
May 18, 2026Sell(S)1K$40.25$52K25K
May 18, 2026Sell(S)223$41.21$9K25K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 18, 2026Option exercise(M)5K$0126K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001701247-26-000007) within minutes of acceptance. Every field above traces to the original document. Verify it directly: